Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | AGER | Q15109 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 3/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11961305 | 0.90 | ALDH1A1 (0.53) | ALDH1A1SIGMAR1PTGESALOX5PPARG | |
| SCHEMBL16124149 | 0.88 | ALDH1A1 (0.57) | ALDH1A1SIGMAR1REN | |
| SCHEMBL30958039 | 0.84 | ALDH1A1 (0.61) | ALDH1A1 | |
| SCHEMBL5148707 | 0.84 | ALDH1A1 (0.61) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5148704 | 0.83 | ALDH1A1 (0.63) | ALDH1A1 | |
| SCHEMBL16228399 | 0.81 | LTA4H (0.51) | ALDH1A1KEAP1NFE2L2 | |
| SCHEMBL16228397 | 0.81 | LTA4H (0.51) | ALDH1A1KEAP1NFE2L2 | |
| SCHEMBL10084808 | 0.81 | ACACB (0.55) | PPARG | |
| SCHEMBL13126082 | 0.81 | ACACB (0.55) | PPARG | |
| SCHEMBL12473156 | 0.81 | ACACB (0.55) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970224-B1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| US-20160368946-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2016-12-22 | — | — | US | disclosed |
| US-9434761-B2 | Tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| WO-2014152134-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368946-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTRL, ENPEP | ALDH1A1 1694/4885AGER 688/4885TSHR 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.